About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Diego | 14,679 Studies Near You | Clareo Health

Clinical Trials LocationsSan Diego

Clinical Trials in San Diego

Discover 14,679 clinical trials near San Diego, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11061-11080 of 14,679 trials

COMPLETEDPhase 3< 1 mile

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229

This purpose of this study is to evaluate the safety and efficacy of Licarbazepine for the treatment of manic episodes of bipolar disorder.

Bipolar Disorder

Novartis Pharmaceuticals320 participantsStarted Nov 2004

Little Rock, Arkansas, United States • Cerritos, California, United States • San Diego, California, United States +19 more locations

COMPLETEDPhase 3< 1 mile

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

NCT01128894

This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.

Diabetes Mellitus, Type 2

GlaxoSmithKline841 participantsStarted May 2010

Birmingham, Alabama, United States • Chandler, Arizona, United States • Gilbert, Arizona, United States +170 more locations

Find Trials by Condition in San Diego

Breast Cancerin San Diego Lung Cancerin San Diego Prostate Cancerin San Diego Colorectal Cancerin San Diego Melanomain San Diego Leukemiain San Diego Lymphomain San Diego Pancreatic Cancerin San Diego Ovarian Cancerin San Diego Brain Cancerin San Diego

Data from ClinicalTrials.govTerms

COMPLETED< 1 mile

Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay

NCT02026752

The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1) infected individuals that have viral loads across the dynamic range of the Aptima HIV-1 assay. The plasma samples will be tested in a method comparison study to support the approval of the Aptima HIV-1 assay on Gen-Probe's Panther testing system. The objective of the method comparison study is to evaluate the clinical utility of the Aptima HIV-1 assay by comparing the results to the FDA-licensed COBAS assay (Roche Molecular Systems, Inc., Branchburg, New Jersey) in plasma samples that have viral loads across the dynamic range of the Aptima HIV-1 assay.

HIV-1 Infection

Gen-Probe, Incorporated468 participantsStarted Jan 2014

Palm Springs, California, United States • San Diego, California, United States • New Haven, Connecticut, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

NCT00048308

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.

Cardio-pulmonary BypassCoronary Artery Bypass Graft

Alexion Pharmaceuticals, Inc.3,000 participantsStarted Jan 2002

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +183 more locations

TERMINATEDPhase 4< 1 mile

Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

NCT01574248

Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.

ACE Inhibitor-associated Angioedema

Vanderbilt University Medical Center33 participantsStarted Aug 2011

San Diego, California, United States • Nashville, Tennessee, United States

COMPLETEDPhase 39.6 miles

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834

The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.

Diabetes Mellitus, Type 2

Janssen Research & Development, LLC678 participantsStarted Mar 2010

Phoenix, Arizona, United States • Concord, California, United States • Greenbrae, California, United States +75 more locations

COMPLETEDPhase 411 miles

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

NCT00791895

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S102 participantsStarted Jun 2003

Phoenix, Arizona, United States • La Jolla, California, United States • La Jolla, California, United States +12 more locations

COMPLETED11 miles

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

NCT01819766

This study aims to determine the performance of the Exact IBD-ACRN surveillance test to detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel disease (IBD). Patients with an IBD diagnosis for at least eight years or diagnosis of primary sclerosing cholangitis (PSC) and who are eligible for CRC screening are eligible to participate in this study. Enrolled subjects will collect a stool sample for the Exact IBD-ACRN surveillance test. Subjects must have undergone colonoscopy no more than 90 days prior to enrollment and will undergo colonoscopy or surgical intervention within 120 days of enrollment. Tissue diagnosis of CRC will be established by histopathologic examination.

Inflammatory Bowel Disease (IBD)Primary Sclerosing Cholangitis (PSC)Colorectal Neoplasms+1 more

Exact Sciences Corporation440 participantsStarted Mar 2013

Phoenix, Arizona, United States • La Jolla, California, United States • Miami, Florida, United States +23 more locations

COMPLETEDPhase 1/211 miles

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

NCT01220271

The purpose of this trial is to show proof of concept that by blocking the Transforming Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical benefit. Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with radiochemotherapy with temozolomide for Phase 2 in patients with glioma eligible to receive radiochemotherapy with temozolomide (e.g. newly diagnosed malignant glioma World Health Organization Grade III and IV). Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in combination with standard radiochemotherapy in patients with newly diagnosed glioblastoma.

Eli Lilly and Company75 participantsStarted Apr 2011

La Jolla, California, United States • San Francisco, California, United States • Tampa, Florida, United States +7 more locations

COMPLETEDPhase 384 miles

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

NCT00713648

The trial is conducted in Europe, North America and Asia. The aim of this trial is to evaluate catridecacog (recombinant factor XIII (rFXIII)) treatment in patients with inherited FXIII deficiency. It is expected that recombinant FXIII can be used for the prevention of bleeding episodes.

Congenital Bleeding DisorderCongenital FXIII Deficiency

Novo Nordisk A/S41 participantsStarted Aug 2008

Phoenix, Arizona, United States • Orange, California, United States • Tampa, Florida, United States +32 more locations

COMPLETEDPhase 284 miles

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

NCT01044186

The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional iron overload with a documented inability to tolerate any of the commercially available iron chelators due to severe toxicity rendering continued therapy either impossible or hazardous. Patients who were also ineligible for all on-going registration trials with ICL670 were included in the study. In exceptional cases, patients with a degree of iron overload which was not immediately life-threatening and who were ineligible for the registration trials were also enrolled provided they had a well-documented, sound justification for alternative chelation therapy.

Transfusional Iron Overload

Novartis Pharmaceuticals30 participantsStarted Jun 2003

Oakland, California, United States • Orange, California, United States • Boston, Massachusetts, United States +15 more locations

COMPLETEDPhase 384 miles

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907

This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and carboplatin. It is not yet known whether glutathione is more effective than a placebo in preventing peripheral neuropathy.

Chemotherapeutic Agent ToxicityNeuropathyNeurotoxicity Syndrome+13 more

Alliance for Clinical Trials in Oncology195 participantsStarted Dec 2009

Mobile, Alabama, United States • Fairbanks, Alaska, United States • Scottsdale, Arizona, United States +387 more locations

COMPLETEDPhase 2109 miles

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

NCT01993641

The purpose of this open label study is to determine whether combining pracinostat (study drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in Myelodysplastic Syndrome (MDS) patients who have failed an initial single agent hypomethylating agent (HMA), and to provide additional safety and efficacy data.

Myelodysplastic SyndromeMDS

Helsinn Healthcare SA45 participantsStarted Dec 2013

Mobile, Alabama, United States • Duarte, California, United States • Los Angeles, California, United States +18 more locations

COMPLETEDPhase 2111 miles

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

NCT00659789

Current management of HIV infection includes anti-retroviral therapy (ART). ART cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. Furthermore, ART side effects often require medication that increases the inconveniences and financial burdens of HIV management. Of further concern is the emergence of viruses resistant to ART that can result in treatment failure. ART-free periods could provide substantial benefit. Vacc-4x is a peptide-based HIV immunotherapy that is proposed for prolongation of ART-free periods. The purpose of this study is to determine whether Vacc-4x immunotherapy can give safe ART-free period.

HIV I Infection

Bionor Immuno AS137 participantsStarted Aug 2008

Los Angeles, California, United States • Los Angeles, California, United States • Sacramento, California, United States +15 more locations

COMPLETEDPhase 3114 miles

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

NCT01731938

This study is designed to assess the safety and efficacy of fibrin sealant (FS) Grifols in patients undergoing elective (non-emergency) soft tissue open surgery where bleeding may be present. The purpose of this study is to demonstrate that FS Grifols is not inferior to commercially-available oxidized cellulose pads (Surgicel®) in providing benefit in the time to hemostasis (i.e, the stoppage of bleeding). This study has a Preliminary Part (I) for study teams to become familiar with the application of FS Grifols and a Primary Part (II) to assess the safety and efficacy of FS Grifols. In both parts of the study, patients will be randomized in a 1:1 ratio to either FS Grifols or Surgicel.

Soft Tissue Surgical Bleeding

Grifols Biologicals, LLC327 participantsStarted Nov 2012

Florence, Alabama, United States • Pasadena, California, United States • Bridgeport, Connecticut, United States +22 more locations

COMPLETEDPhase 4265 miles

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

NCT01165684

This trial is conducted in Europe, and North and South America. The aim of this clinical trial is to investigate if the two treatments are equally effective.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S401 participantsStarted Oct 2010

Birmingham, Alabama, United States • Mesa, Arizona, United States • Scottsdale, Arizona, United States +64 more locations

COMPLETEDNA458 miles

Remote Access to Care, Everywhere, for Parkinson Disease

NCT02144220

The primary objective of this study is to evaluate the feasibility, efficacy and the value of providing care to individuals with Parkinson disease directly into their homes. The specific aims are: 1. To demonstrate the feasibility of conducting remote evaluations of patients with Parkinson disease nationally; 2. To measure the impact of remote care on each patient's ability to improve his or her quality of life (QoL) and better manage his or her Parkinson disease; and 3. To assess the long-term acceptability to patients in receiving ongoing care remotely via telemedicine.

Parkinson Disease

University of Rochester277 participantsStarted Mar 2014

San Francisco, California, United States • Gainesville, Florida, United States • Rochester, New York, United States

COMPLETEDPhase 2458 miles

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

NCT00057785

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more comfortably. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of specialized radiation therapy techniques with or without chemotherapy in reducing mouth dryness in patients who have nasopharyngeal cancer.

Head and Neck CancerOral Complications of Radiation TherapyRadiation Toxicity

Radiation Therapy Oncology Group68 participantsStarted Feb 2003

Birmingham, Alabama, United States • Davis, California, United States • Sacramento, California, United States +14 more locations

COMPLETEDPhase 31133 miles

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

NCT01127750

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

Relapsing Multiple Sclerosis

Novartis2,417 participantsStarted May 2010

Box Hill, Australia • Heidelberg, Australia • Kogarah, Australia +286 more locations

COMPLETEDPhase 21183 miles

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT00986414

This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskinesias.

Parkinson DiseaseDyskinesias

Novartis260 participantsStarted Sep 2009

East Gosford, Australia • Heidelberg, Australia • Melbourne, Australia +44 more locations

PreviousPage 554 of 734Next

Diabetes

in San Diego

Heart Diseasein San Diego